Phase 2a study of the dual SYK/JAK inhibitor cerdulatinib (ALXN2075) as monotherapy in patients with relapsed/refractory peripheral T-cell lymphoma Meeting Abstract
| Authors: | Horwitz, S. M.; Feldman, T. A.; Ye, J. C.; Khodadoust, M. S.; Munoz, J.; Hamlin, P. A.; Kim, Y. H.; Wilcox, R. A.; Patel, M. R.; Coffey, G. P.; Osman, M.; Holland, J. S.; Guzman, C. B.; Smith, S. M. |
| Abstract Title: | Phase 2a study of the dual SYK/JAK inhibitor cerdulatinib (ALXN2075) as monotherapy in patients with relapsed/refractory peripheral T-cell lymphoma |
| Meeting Title: | 63rd Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 138 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2021 Dec 11-14 |
| Meeting Location: | Atlanta, GA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2021-11-23 |
| Language: | English |
| ACCESSION: | WOS:000736398802162 |
| DOI: | 10.1182/blood-2021-148352 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 622 -- Hybrid meeting, also took place online -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
